CELESTCenter of Excellence for Learning in Education Science and Technology (Boston, MA)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The CELEST study evaluated upadacitinib in adult patients with moderately to severely active Crohn's disease and inadequate response/intolerance to an immunomodulator or tumor necrosis factor alpha antagonist (TNF-a).
Two additional sub-analyses of the 16-week CELEST induction data, one evaluating the onset of clinical remission and response, and one evaluating the potential to achieve steroid-free endoscopic/clinical remission/response, were also presented at ECCO.
CELEST is a 52-week, Phase 2, randomized, double-blind study consisting of a 16-week dose-ranging induction and 36-week extension phase.